#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3 .
1-1	0-1	3	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=The aim of this study was to elucidate the rMnSOD-dependent nSMase changes and their role in the protective-preventive effect from ionizing radiation in the brain .
3-1	15-18	The	abstract[3]	new[3]	coref	11-6[63_3]
3-2	19-22	aim	abstract[3]	new[3]	_	_
3-3	23-25	of	abstract[3]	new[3]	_	_
3-4	26-30	this	abstract[3]|abstract[4]	new[3]|new[4]	coref	11-1[62_4]
3-5	31-36	study	abstract[3]|abstract[4]	new[3]|new[4]	_	_
3-6	37-40	was	_	_	_	_
3-7	41-43	to	_	_	_	_
3-8	44-53	elucidate	_	_	_	_
3-9	54-57	the	abstract[5]|abstract[6]	new[5]|new[6]	_	_
3-10	58-74	rMnSOD-dependent	abstract[5]|abstract[6]	new[5]|new[6]	_	_
3-11	75-81	nSMase	abstract[5]|abstract[6]	new[5]|new[6]	_	_
3-12	82-89	changes	abstract[5]|abstract[6]	new[5]|new[6]	_	_
3-13	90-93	and	abstract[6]	new[6]	_	_
3-14	94-99	their	abstract[6]|abstract[7]	new[6]|new[7]	coref	9-5[45_7]
3-15	100-104	role	abstract[6]|abstract[7]	new[6]|new[7]	_	_
3-16	105-107	in	_	_	_	_
3-17	108-111	the	abstract[8]	new[8]	coref	8-1[39_8]
3-18	112-133	protective-preventive	abstract[8]	new[8]	_	_
3-19	134-140	effect	abstract[8]	new[8]	_	_
3-20	141-145	from	abstract[8]	new[8]	_	_
3-21	146-154	ionizing	abstract[8]|abstract[9]	new[8]|new[9]	coref	4-5[13_9]
3-22	155-164	radiation	abstract[8]|abstract[9]	new[8]|new[9]	_	_
3-23	165-167	in	abstract[8]|abstract[9]	new[8]|new[9]	_	_
3-24	168-171	the	abstract[8]|abstract[9]|object[10]	new[8]|new[9]|new[10]	coref	8-6[0_10]
3-25	172-177	brain	abstract[8]|abstract[9]|object[10]	new[8]|new[9]|new[10]	_	_
3-26	178-179	.	_	_	_	_

#Text=Mice were exposed to a set of minor γ radiation and neutrons and a spectrum of neutrons , simulating the radiation levels to which cosmonauts will be exposed during deep-space , long-term missions .
4-1	180-184	Mice	animal	new	_	_
4-2	185-189	were	_	_	_	_
4-3	190-197	exposed	_	_	_	_
4-4	198-200	to	_	_	_	_
4-5	201-202	a	abstract[13]	giv[13]	coref	4-21[0_13]
4-6	203-206	set	abstract[13]	giv[13]	_	_
4-7	207-209	of	abstract[13]	giv[13]	_	_
4-8	210-215	minor	abstract[13]	giv[13]	_	_
4-9	216-217	γ	place|abstract[13]	new|giv[13]	coref	5-9
4-10	218-227	radiation	abstract[13]	giv[13]	_	_
4-11	228-231	and	_	_	_	_
4-12	232-240	neutrons	substance	new	coref	4-17
4-13	241-244	and	_	_	_	_
4-14	245-246	a	abstract[15]	new[15]	_	_
4-15	247-255	spectrum	abstract[15]	new[15]	_	_
4-16	256-258	of	abstract[15]	new[15]	_	_
4-17	259-267	neutrons	abstract[15]|substance	new[15]|giv	_	_
4-18	268-269	,	_	_	_	_
4-19	270-280	simulating	_	_	_	_
4-20	281-284	the	abstract[18]	new[18]	coref	15-9[101_18]
4-21	285-294	radiation	abstract|abstract[18]	giv|new[18]	coref	5-9[25_0]
4-22	295-301	levels	abstract[18]	new[18]	_	_
4-23	302-304	to	_	_	_	_
4-24	305-310	which	_	_	_	_
4-25	311-321	cosmonauts	person	new	_	_
4-26	322-326	will	_	_	_	_
4-27	327-329	be	_	_	_	_
4-28	330-337	exposed	_	_	_	_
4-29	338-344	during	_	_	_	_
4-30	345-355	deep-space	abstract	new	_	_
4-31	356-357	,	_	_	_	_
4-32	358-367	long-term	event[21]	new[21]	_	_
4-33	368-376	missions	event[21]	new[21]	_	_
4-34	377-378	.	_	_	_	_

#Text=At the moment we do not know whether γ radiation only was unable to induce nSMase activation .
5-1	379-381	At	_	_	_	_
5-2	382-385	the	time[22]	new[22]	coref	19-2[136_22]
5-3	386-392	moment	time[22]	new[22]	_	_
5-4	393-395	we	person	acc	ana	6-1
5-5	396-398	do	_	_	_	_
5-6	399-402	not	_	_	_	_
5-7	403-407	know	_	_	_	_
5-8	408-415	whether	_	_	_	_
5-9	416-417	γ	place|abstract[25]	giv|giv[25]	coref|coref	8-4[40_25]|8-4[40_25]
5-10	418-427	radiation	abstract[25]	giv[25]	_	_
5-11	428-432	only	_	_	_	_
5-12	433-436	was	_	_	_	_
5-13	437-443	unable	_	_	_	_
5-14	444-446	to	_	_	_	_
5-15	447-453	induce	_	_	_	_
5-16	454-460	nSMase	abstract[26]	new[26]	_	_
5-17	461-471	activation	abstract[26]	new[26]	_	_
5-18	472-473	.	_	_	_	_

#Text=We show that rMnSOD particles are capable to cross the blood-brain barrier and localize in the midbrain .
6-1	474-476	We	person	giv	ana	10-1
6-2	477-481	show	_	_	_	_
6-3	482-486	that	_	_	_	_
6-4	487-493	rMnSOD	object[28]	new[28]	_	_
6-5	494-503	particles	object[28]	new[28]	_	_
6-6	504-507	are	_	_	_	_
6-7	508-515	capable	_	_	_	_
6-8	516-518	to	_	_	_	_
6-9	519-524	cross	_	_	_	_
6-10	525-528	the	abstract[29]	new[29]	_	_
6-11	529-540	blood-brain	abstract[29]	new[29]	_	_
6-12	541-548	barrier	abstract[29]	new[29]	_	_
6-13	549-552	and	_	_	_	_
6-14	553-561	localize	_	_	_	_
6-15	562-564	in	_	_	_	_
6-16	565-568	the	place[30]	new[30]	_	_
6-17	569-577	midbrain	place[30]	new[30]	_	_
6-18	578-579	.	_	_	_	_

#Text=Here , rMnSOD has the ability to limit radiation-induced damage , such as the loss of neuron number and the alteration of neurofilaments .
7-1	580-584	Here	_	_	_	_
7-2	585-586	,	_	_	_	_
7-3	587-593	rMnSOD	substance	new	coref	9-9
7-4	594-597	has	_	_	_	_
7-5	598-601	the	abstract[32]	new[32]	_	_
7-6	602-609	ability	abstract[32]	new[32]	_	_
7-7	610-612	to	_	_	_	_
7-8	613-618	limit	_	_	_	_
7-9	619-636	radiation-induced	abstract[33]	new[33]	coref	8-6[42_33]
7-10	637-643	damage	abstract[33]	new[33]	_	_
7-11	644-645	,	abstract[33]	new[33]	_	_
7-12	646-650	such	abstract[33]	new[33]	_	_
7-13	651-653	as	abstract[33]	new[33]	_	_
7-14	654-657	the	abstract[33]|abstract[34]	new[33]|new[34]	_	_
7-15	658-662	loss	abstract[33]|abstract[34]	new[33]|new[34]	_	_
7-16	663-665	of	abstract[33]|abstract[34]	new[33]|new[34]	_	_
7-17	666-672	neuron	abstract[33]|abstract[34]|object|abstract[36]	new[33]|new[34]|new|new[36]	_	_
7-18	673-679	number	abstract[33]|abstract[34]|abstract[36]	new[33]|new[34]|new[36]	_	_
7-19	680-683	and	abstract[33]|abstract[34]	new[33]|new[34]	_	_
7-20	684-687	the	abstract[33]|abstract[34]|abstract[37]	new[33]|new[34]|new[37]	_	_
7-21	688-698	alteration	abstract[33]|abstract[34]|abstract[37]	new[33]|new[34]|new[37]	_	_
7-22	699-701	of	abstract[33]|abstract[34]|abstract[37]	new[33]|new[34]|new[37]	_	_
7-23	702-716	neurofilaments	abstract[33]|abstract[34]|abstract[37]|object	new[33]|new[34]|new[37]|new	_	_
7-24	717-718	.	_	_	_	_

#Text=The effect of radiation on brain damage has previously been reported by other authors .
8-1	719-722	The	abstract[39]	giv[39]	coref	9-20[52_39]
8-2	723-729	effect	abstract[39]	giv[39]	_	_
8-3	730-732	of	abstract[39]	giv[39]	_	_
8-4	733-742	radiation	abstract[39]|abstract[40]	giv[39]|giv[40]	ana	9-20[0_40]
8-5	743-745	on	abstract[39]|abstract[40]	giv[39]|giv[40]	_	_
8-6	746-751	brain	abstract[39]|abstract[40]|object|abstract[42]	giv[39]|giv[40]|giv|giv[42]	coref|coref|coref|coref	20-16|22-17[166_42]|20-16|22-17[166_42]
8-7	752-758	damage	abstract[39]|abstract[40]|abstract[42]	giv[39]|giv[40]|giv[42]	_	_
8-8	759-762	has	_	_	_	_
8-9	763-773	previously	_	_	_	_
8-10	774-778	been	_	_	_	_
8-11	779-787	reported	_	_	_	_
8-12	788-790	by	_	_	_	_
8-13	791-796	other	person[43]	new[43]	_	_
8-14	797-804	authors	person[43]	new[43]	_	_
8-15	805-806	.	_	_	_	_

#Text=Although many studies elucidated the radioprotective role of rMnSOD through antioxidant mechanisms in mitochondria , no data exist about its effect on nSMase .
9-1	807-815	Although	_	_	_	_
9-2	816-820	many	abstract[44]	new[44]	_	_
9-3	821-828	studies	abstract[44]	new[44]	_	_
9-4	829-839	elucidated	_	_	_	_
9-5	840-843	the	abstract[45]	giv[45]	coref	14-9[90_45]
9-6	844-859	radioprotective	abstract[45]	giv[45]	_	_
9-7	860-864	role	abstract[45]	giv[45]	_	_
9-8	865-867	of	abstract[45]	giv[45]	_	_
9-9	868-874	rMnSOD	abstract[45]|substance	giv[45]|giv	coref	10-4
9-10	875-882	through	_	_	_	_
9-11	883-894	antioxidant	abstract|abstract[48]	new|new[48]	_	_
9-12	895-905	mechanisms	abstract[48]	new[48]	_	_
9-13	906-908	in	abstract[48]	new[48]	_	_
9-14	909-921	mitochondria	abstract[48]|place	new[48]|new	_	_
9-15	922-923	,	_	_	_	_
9-16	924-926	no	abstract[50]	new[50]	coref	20-4[148_50]
9-17	927-931	data	abstract[50]	new[50]	_	_
9-18	932-937	exist	_	_	_	_
9-19	938-943	about	_	_	_	_
9-20	944-947	its	abstract|abstract[52]	giv|giv[52]	coref|coref|coref|coref	11-20[68_52]|13-12|11-20[68_52]|13-12
9-21	948-954	effect	abstract[52]	giv[52]	_	_
9-22	955-957	on	abstract[52]	giv[52]	_	_
9-23	958-964	nSMase	abstract[52]|abstract	giv[52]|new	coref	11-13
9-24	965-966	.	_	_	_	_

#Text=We show that rMnSOD stimulates nSMase gene and protein expression and enzymatic activity .
10-1	967-969	We	person	giv	ana	15-6
10-2	970-974	show	_	_	_	_
10-3	975-979	that	_	_	_	_
10-4	980-986	rMnSOD	abstract	giv	coref	11-18
10-5	987-997	stimulates	_	_	_	_
10-6	998-1004	nSMase	abstract[56]|abstract[57]|abstract[59]	new[56]|new[57]|new[59]	coref|coref|coref|coref|coref|coref|coref|coref|coref	12-10[77_56]|12-10[78_57]|12-14[80_59]|12-10[77_56]|12-10[78_57]|12-14[80_59]|12-10[77_56]|12-10[78_57]|12-14[80_59]
10-7	1005-1009	gene	abstract[56]|abstract[57]|abstract[59]	new[56]|new[57]|new[59]	_	_
10-8	1010-1013	and	abstract[57]|abstract[59]	new[57]|new[59]	_	_
10-9	1014-1021	protein	abstract[57]|substance|abstract[59]	new[57]|new|new[59]	coref	12-14
10-10	1022-1032	expression	abstract[59]	new[59]	_	_
10-11	1033-1036	and	_	_	_	_
10-12	1037-1046	enzymatic	place|abstract[61]	new|new[61]	coref|coref	18-30[135_61]|18-30[135_61]
10-13	1047-1055	activity	abstract[61]	new[61]	_	_
10-14	1056-1057	.	_	_	_	_

#Text=The study was articulated with the aim of analyzing the response of nSMase in samples in which rMnSOD has a protective effect ( non-pretreated samples ) and in samples in which rMnSOD has a preventive effect ( pretreated samples ) .
11-1	1058-1061	The	abstract[62]	giv[62]	coref	12-4[75_62]
11-2	1062-1067	study	abstract[62]	giv[62]	_	_
11-3	1068-1071	was	_	_	_	_
11-4	1072-1083	articulated	_	_	_	_
11-5	1084-1088	with	_	_	_	_
11-6	1089-1092	the	abstract[63]	giv[63]	_	_
11-7	1093-1096	aim	abstract[63]	giv[63]	_	_
11-8	1097-1099	of	_	_	_	_
11-9	1100-1109	analyzing	_	_	_	_
11-10	1110-1113	the	abstract[64]	new[64]	_	_
11-11	1114-1122	response	abstract[64]	new[64]	_	_
11-12	1123-1125	of	abstract[64]	new[64]	_	_
11-13	1126-1132	nSMase	abstract[64]|abstract	new[64]|giv	coref	14-7
11-14	1133-1135	in	abstract[64]	new[64]	_	_
11-15	1136-1143	samples	abstract[64]|object	new[64]|new	appos	11-24[69_0]
11-16	1144-1146	in	_	_	_	_
11-17	1147-1152	which	_	_	_	_
11-18	1153-1159	rMnSOD	abstract	giv	coref	11-32
11-19	1160-1163	has	_	_	_	_
11-20	1164-1165	a	abstract[68]	giv[68]	coref	11-34[71_68]
11-21	1166-1176	protective	abstract[68]	giv[68]	_	_
11-22	1177-1183	effect	abstract[68]	giv[68]	_	_
11-23	1184-1185	(	_	_	_	_
11-24	1186-1200	non-pretreated	object[69]	giv[69]	appos	11-38[72_69]
11-25	1201-1208	samples	object[69]	giv[69]	_	_
11-26	1209-1210	)	_	_	_	_
11-27	1211-1214	and	_	_	_	_
11-28	1215-1217	in	_	_	_	_
11-29	1218-1225	samples	_	_	_	_
11-30	1226-1228	in	_	_	_	_
11-31	1229-1234	which	_	_	_	_
11-32	1235-1241	rMnSOD	abstract	giv	coref	12-8
11-33	1242-1245	has	_	_	_	_
11-34	1246-1247	a	abstract[71]	giv[71]	coref	12-5[0_71]
11-35	1248-1258	preventive	abstract[71]	giv[71]	_	_
11-36	1259-1265	effect	abstract[71]	giv[71]	_	_
11-37	1266-1267	(	_	_	_	_
11-38	1268-1278	pretreated	object[72]	giv[72]	coref	12-2[73_72]
11-39	1279-1286	samples	object[72]	giv[72]	_	_
11-40	1287-1288	)	_	_	_	_
11-41	1289-1290	.	_	_	_	_

#Text=In samples for protective effect study , rMnSOD increases strongly nSMase gene and protein expression in irradiated samples in a dose-dependent manner .
12-1	1291-1293	In	_	_	_	_
12-2	1294-1301	samples	object[73]	giv[73]	coref	12-17[81_73]
12-3	1302-1305	for	object[73]	giv[73]	_	_
12-4	1306-1316	protective	object[73]|abstract[75]	giv[73]|giv[75]	_	_
12-5	1317-1323	effect	object[73]|abstract|abstract[75]	giv[73]|giv|giv[75]	coref	18-5
12-6	1324-1329	study	object[73]|abstract[75]	giv[73]|giv[75]	_	_
12-7	1330-1331	,	_	_	_	_
12-8	1332-1338	rMnSOD	substance	giv	coref	15-21
12-9	1339-1348	increases	_	_	_	_
12-10	1349-1357	strongly	abstract[77]|abstract[78]	giv[77]|giv[78]	coref|coref|coref|coref	18-8[126_77]|18-8[127_78]|18-8[126_77]|18-8[127_78]
12-11	1358-1364	nSMase	abstract[77]|abstract[78]	giv[77]|giv[78]	_	_
12-12	1365-1369	gene	abstract[77]|abstract[78]	giv[77]|giv[78]	_	_
12-13	1370-1373	and	abstract[78]	giv[78]	_	_
12-14	1374-1381	protein	abstract[78]|substance|abstract[80]	giv[78]|giv|giv[80]	coref|coref|coref|coref	18-11|18-11[129_80]|18-11|18-11[129_80]
12-15	1382-1392	expression	abstract[78]|abstract[80]	giv[78]|giv[80]	_	_
12-16	1393-1395	in	_	_	_	_
12-17	1396-1406	irradiated	object[81]	giv[81]	coref	18-2[122_81]
12-18	1407-1414	samples	object[81]	giv[81]	_	_
12-19	1415-1417	in	object[81]	giv[81]	_	_
12-20	1418-1419	a	object[81]|abstract[82]	giv[81]|new[82]	_	_
12-21	1420-1434	dose-dependent	object[81]|abstract[82]	giv[81]|new[82]	_	_
12-22	1435-1441	manner	object[81]|abstract[82]	giv[81]|new[82]	_	_
12-23	1442-1443	.	_	_	_	_

#Text=Small variations of nSMase enzyme activities are obtained only with high radiation doses .
13-1	1444-1449	Small	abstract[83]	new[83]	_	_
13-2	1450-1460	variations	abstract[83]	new[83]	_	_
13-3	1461-1463	of	abstract[83]	new[83]	_	_
13-4	1464-1470	nSMase	abstract[83]|abstract[85]	new[83]|new[85]	_	_
13-5	1471-1477	enzyme	abstract[83]|substance|abstract[85]	new[83]|new|new[85]	coref	16-26[112_0]
13-6	1478-1488	activities	abstract[83]|abstract[85]	new[83]|new[85]	_	_
13-7	1489-1492	are	_	_	_	_
13-8	1493-1501	obtained	_	_	_	_
13-9	1502-1506	only	_	_	_	_
13-10	1507-1511	with	_	_	_	_
13-11	1512-1516	high	abstract[87]	new[87]	_	_
13-12	1517-1526	radiation	abstract|abstract[87]	giv|new[87]	coref	15-10
13-13	1527-1532	doses	abstract[87]	new[87]	_	_
13-14	1533-1534	.	_	_	_	_

#Text=This observation is relevant , as nSMase plays a crucial role in the regulation of ROS generation and in the maintenance of homeostasis between proapoptotic and prosurvival signals .
14-1	1535-1539	This	abstract[88]	new[88]	_	_
14-2	1540-1551	observation	abstract[88]	new[88]	_	_
14-3	1552-1554	is	_	_	_	_
14-4	1555-1563	relevant	_	_	_	_
14-5	1564-1565	,	_	_	_	_
14-6	1566-1568	as	_	_	_	_
14-7	1569-1575	nSMase	substance	giv	coref	16-7
14-8	1576-1581	plays	_	_	_	_
14-9	1582-1583	a	abstract[90]	giv[90]	_	_
14-10	1584-1591	crucial	abstract[90]	giv[90]	_	_
14-11	1592-1596	role	abstract[90]	giv[90]	_	_
14-12	1597-1599	in	abstract[90]	giv[90]	_	_
14-13	1600-1603	the	abstract[90]|abstract[91]	giv[90]|new[91]	_	_
14-14	1604-1614	regulation	abstract[90]|abstract[91]	giv[90]|new[91]	_	_
14-15	1615-1617	of	abstract[90]|abstract[91]	giv[90]|new[91]	_	_
14-16	1618-1621	ROS	abstract[90]|abstract[91]|substance|abstract[93]	giv[90]|new[91]|new|new[93]	coref|coref	20-25|20-25
14-17	1622-1632	generation	abstract[90]|abstract[91]|abstract[93]	giv[90]|new[91]|new[93]	_	_
14-18	1633-1636	and	_	_	_	_
14-19	1637-1639	in	_	_	_	_
14-20	1640-1643	the	abstract[94]	new[94]	_	_
14-21	1644-1655	maintenance	abstract[94]	new[94]	_	_
14-22	1656-1658	of	abstract[94]	new[94]	_	_
14-23	1659-1670	homeostasis	abstract[94]|abstract[95]	new[94]|new[95]	_	_
14-24	1671-1678	between	abstract[94]|abstract[95]	new[94]|new[95]	_	_
14-25	1679-1691	proapoptotic	abstract[94]|abstract[95]|abstract|abstract[98]	new[94]|new[95]|new|new[98]	_	_
14-26	1692-1695	and	abstract[94]|abstract[95]|abstract[98]	new[94]|new[95]|new[98]	_	_
14-27	1696-1707	prosurvival	abstract[94]|abstract[95]|event|abstract[98]	new[94]|new[95]|new|new[98]	_	_
14-28	1708-1715	signals	abstract[94]|abstract[95]|abstract[98]	new[94]|new[95]|new[98]	_	_
14-29	1716-1717	.	_	_	_	_

#Text=In line with this , we show that highest radiation levels induce significant nSMase responses only in the presence of rMnSOD .
15-1	1718-1720	In	_	_	_	_
15-2	1721-1725	line	_	_	_	_
15-3	1726-1730	with	_	_	_	_
15-4	1731-1735	this	_	_	_	_
15-5	1736-1737	,	_	_	_	_
15-6	1738-1740	we	person	giv	ana	16-17
15-7	1741-1745	show	_	_	_	_
15-8	1746-1750	that	_	_	_	_
15-9	1751-1758	highest	abstract[101]	giv[101]	coref	19-9[138_101]
15-10	1759-1768	radiation	abstract|abstract[101]	giv|giv[101]	coref	20-20
15-11	1769-1775	levels	abstract[101]	giv[101]	_	_
15-12	1776-1782	induce	_	_	_	_
15-13	1783-1794	significant	abstract[102]	new[102]	_	_
15-14	1795-1801	nSMase	abstract[102]	new[102]	_	_
15-15	1802-1811	responses	abstract[102]	new[102]	_	_
15-16	1812-1816	only	abstract[103]	new[103]	_	_
15-17	1817-1819	in	abstract[103]	new[103]	_	_
15-18	1820-1823	the	abstract[103]	new[103]	_	_
15-19	1824-1832	presence	abstract[103]	new[103]	_	_
15-20	1833-1835	of	abstract[103]	new[103]	_	_
15-21	1836-1842	rMnSOD	abstract[103]|substance	new[103]|giv	coref	16-15
15-22	1843-1844	.	_	_	_	_

#Text=Although the present results indicate that nSMase may be required for the action of rMnSOD , we cannot prove the direct action of rMnSOD on this enzyme .
16-1	1845-1853	Although	_	_	_	_
16-2	1854-1857	the	abstract[105]	new[105]	_	_
16-3	1858-1865	present	abstract[105]	new[105]	_	_
16-4	1866-1873	results	abstract[105]	new[105]	_	_
16-5	1874-1882	indicate	_	_	_	_
16-6	1883-1887	that	_	_	_	_
16-7	1888-1894	nSMase	substance	giv	coref	21-6
16-8	1895-1898	may	_	_	_	_
16-9	1899-1901	be	_	_	_	_
16-10	1902-1910	required	_	_	_	_
16-11	1911-1914	for	_	_	_	_
16-12	1915-1918	the	abstract[107]	new[107]	_	_
16-13	1919-1925	action	abstract[107]	new[107]	_	_
16-14	1926-1928	of	abstract[107]	new[107]	_	_
16-15	1929-1935	rMnSOD	abstract[107]|substance	new[107]|giv	coref	16-24[111_0]
16-16	1936-1937	,	_	_	_	_
16-17	1938-1940	we	person	giv	ana	17-2
16-18	1941-1947	cannot	_	_	_	_
16-19	1948-1953	prove	_	_	_	_
16-20	1954-1957	the	abstract[110]	new[110]	ana	17-5[0_110]
16-21	1958-1964	direct	abstract[110]	new[110]	_	_
16-22	1965-1971	action	abstract[110]	new[110]	_	_
16-23	1972-1974	of	abstract[110]	new[110]	_	_
16-24	1975-1981	rMnSOD	abstract[110]|substance[111]	new[110]|giv[111]	coref	17-17[0_111]
16-25	1982-1984	on	abstract[110]|substance[111]	new[110]|giv[111]	_	_
16-26	1985-1989	this	abstract[110]|substance[111]|substance[112]	new[110]|giv[111]|giv[112]	coref	18-31[0_112]
16-27	1990-1996	enzyme	abstract[110]|substance[111]|substance[112]	new[110]|giv[111]|giv[112]	_	_
16-28	1997-1998	.	_	_	_	_

#Text=To our knowledge , this is the first study indicating SMase as a potential effector of rMnSOD during its protection action .
17-1	1999-2001	To	_	_	_	_
17-2	2002-2005	our	person|abstract[114]	giv|new[114]	ana|ana	19-4|19-4
17-3	2006-2015	knowledge	abstract[114]	new[114]	_	_
17-4	2016-2017	,	_	_	_	_
17-5	2018-2022	this	abstract	giv	coref	17-7[116_0]
17-6	2023-2025	is	_	_	_	_
17-7	2026-2029	the	abstract[116]	giv[116]	coref	17-19[121_116]
17-8	2030-2035	first	abstract[116]	giv[116]	_	_
17-9	2036-2041	study	abstract[116]	giv[116]	_	_
17-10	2042-2052	indicating	_	_	_	_
17-11	2053-2058	SMase	abstract	new	_	_
17-12	2059-2061	as	_	_	_	_
17-13	2062-2063	a	_	_	_	_
17-14	2064-2073	potential	_	_	_	_
17-15	2074-2082	effector	_	_	_	_
17-16	2083-2085	of	_	_	_	_
17-17	2086-2092	rMnSOD	substance	giv	ana	17-19
17-18	2093-2099	during	_	_	_	_
17-19	2100-2103	its	substance|abstract[121]	giv|giv[121]	coref|coref|coref|coref	18-4[125_121]|18-26|18-4[125_121]|18-26
17-20	2104-2114	protection	abstract|abstract[121]	new|giv[121]	_	_
17-21	2115-2121	action	abstract[121]	giv[121]	_	_
17-22	2122-2123	.	_	_	_	_

#Text=In samples for preventive effect study , nSMase gene and protein expression is reduced in comparison with the samples in which the protective effect of rMnSOD is studied but the enzyme activity is much higher .
18-1	2124-2126	In	_	_	_	_
18-2	2127-2134	samples	object[122]	giv[122]	coref	18-18[131_122]
18-3	2135-2138	for	object[122]	giv[122]	_	_
18-4	2139-2149	preventive	object[122]|abstract|abstract[125]	giv[122]|new|giv[125]	_	_
18-5	2150-2156	effect	object[122]|abstract|abstract[125]	giv[122]|giv|giv[125]	_	_
18-6	2157-2162	study	object[122]|abstract[125]	giv[122]|giv[125]	_	_
18-7	2163-2164	,	_	_	_	_
18-8	2165-2171	nSMase	abstract[126]|abstract[127]	giv[126]|giv[127]	coref|coref	19-36[0_126]|19-36[0_126]
18-9	2172-2176	gene	abstract[126]|abstract[127]	giv[126]|giv[127]	_	_
18-10	2177-2180	and	abstract[127]	giv[127]	_	_
18-11	2181-2188	protein	abstract[127]|substance|abstract[129]	giv[127]|giv|giv[129]	coref|coref	19-35[147_129]|19-35[147_129]
18-12	2189-2199	expression	abstract[127]|abstract[129]	giv[127]|giv[129]	_	_
18-13	2200-2202	is	_	_	_	_
18-14	2203-2210	reduced	_	_	_	_
18-15	2211-2213	in	_	_	_	_
18-16	2214-2224	comparison	abstract[130]	new[130]	_	_
18-17	2225-2229	with	abstract[130]	new[130]	_	_
18-18	2230-2233	the	abstract[130]|object[131]	new[130]|giv[131]	_	_
18-19	2234-2241	samples	abstract[130]|object[131]	new[130]|giv[131]	_	_
18-20	2242-2244	in	_	_	_	_
18-21	2245-2250	which	_	_	_	_
18-22	2251-2254	the	abstract[132]	new[132]	_	_
18-23	2255-2265	protective	abstract[132]	new[132]	_	_
18-24	2266-2272	effect	abstract[132]	new[132]	_	_
18-25	2273-2275	of	abstract[132]	new[132]	_	_
18-26	2276-2282	rMnSOD	abstract[132]|substance	new[132]|giv	_	_
18-27	2283-2285	is	_	_	_	_
18-28	2286-2293	studied	_	_	_	_
18-29	2294-2297	but	_	_	_	_
18-30	2298-2301	the	abstract[135]	giv[135]	_	_
18-31	2302-2308	enzyme	substance|abstract[135]	giv|giv[135]	_	_
18-32	2309-2317	activity	abstract[135]	giv[135]	_	_
18-33	2318-2320	is	_	_	_	_
18-34	2321-2325	much	_	_	_	_
18-35	2326-2332	higher	_	_	_	_
18-36	2333-2334	.	_	_	_	_

#Text=At this moment we can only speculate why nSMase levels are reduced with pretreatment , a possible explanation being that an extended treatment time could stimulate different metabolic patterns , leading to inhibition of nSMase gene expression .
19-1	2335-2337	At	_	_	_	_
19-2	2338-2342	this	time[136]	giv[136]	_	_
19-3	2343-2349	moment	time[136]	giv[136]	_	_
19-4	2350-2352	we	person	giv	ana	20-6
19-5	2353-2356	can	_	_	_	_
19-6	2357-2361	only	_	_	_	_
19-7	2362-2371	speculate	_	_	_	_
19-8	2372-2375	why	_	_	_	_
19-9	2376-2382	nSMase	abstract[138]	giv[138]	coref	20-35[159_138]
19-10	2383-2389	levels	abstract[138]	giv[138]	_	_
19-11	2390-2393	are	_	_	_	_
19-12	2394-2401	reduced	_	_	_	_
19-13	2402-2406	with	_	_	_	_
19-14	2407-2419	pretreatment	abstract	new	appos	19-16[140_0]
19-15	2420-2421	,	_	_	_	_
19-16	2422-2423	a	abstract[140]	giv[140]	_	_
19-17	2424-2432	possible	abstract[140]	giv[140]	_	_
19-18	2433-2444	explanation	abstract[140]	giv[140]	_	_
19-19	2445-2450	being	_	_	_	_
19-20	2451-2455	that	_	_	_	_
19-21	2456-2458	an	time[142]	new[142]	_	_
19-22	2459-2467	extended	time[142]	new[142]	_	_
19-23	2468-2477	treatment	abstract|time[142]	new|new[142]	_	_
19-24	2478-2482	time	time[142]	new[142]	_	_
19-25	2483-2488	could	_	_	_	_
19-26	2489-2498	stimulate	_	_	_	_
19-27	2499-2508	different	abstract[144]	new[144]	_	_
19-28	2509-2518	metabolic	person|abstract[144]	new|new[144]	_	_
19-29	2519-2527	patterns	abstract[144]	new[144]	_	_
19-30	2528-2529	,	_	_	_	_
19-31	2530-2537	leading	_	_	_	_
19-32	2538-2540	to	_	_	_	_
19-33	2541-2551	inhibition	abstract[145]	new[145]	_	_
19-34	2552-2554	of	abstract[145]	new[145]	_	_
19-35	2555-2561	nSMase	abstract[145]|abstract[147]	new[145]|giv[147]	_	_
19-36	2562-2566	gene	abstract[145]|abstract|abstract[147]	new[145]|giv|giv[147]	_	_
19-37	2567-2577	expression	abstract[145]|abstract[147]	new[145]|giv[147]	_	_
19-38	2578-2579	.	_	_	_	_

#Text=Merging already published data with our findings , it is possible to suggest that in brain tissues exposed to radiation , significant amounts of ROS are generated , stimulating nSMase production to significantly increase MnSOD levels .
20-1	2580-2587	Merging	_	_	_	_
20-2	2588-2595	already	_	_	_	_
20-3	2596-2605	published	_	_	_	_
20-4	2606-2610	data	abstract[148]	giv[148]	_	_
20-5	2611-2615	with	abstract[148]	giv[148]	_	_
20-6	2616-2619	our	abstract[148]|person|abstract[150]	giv[148]|giv|new[150]	_	_
20-7	2620-2628	findings	abstract[148]|abstract[150]	giv[148]|new[150]	_	_
20-8	2629-2630	,	_	_	_	_
20-9	2631-2633	it	abstract	new	cata	20-9[0_152]
20-10	2634-2636	is	_	_	_	_
20-11	2637-2645	possible	_	_	_	_
20-12	2646-2648	to	abstract[152]	new[152]	_	_
20-13	2649-2656	suggest	abstract[152]	new[152]	_	_
20-14	2657-2661	that	abstract[152]	new[152]	_	_
20-15	2662-2664	in	abstract[152]	new[152]	_	_
20-16	2665-2670	brain	abstract[152]|object|object[154]	new[152]|giv|new[154]	_	_
20-17	2671-2678	tissues	abstract[152]|object[154]	new[152]|new[154]	_	_
20-18	2679-2686	exposed	abstract[152]	new[152]	_	_
20-19	2687-2689	to	abstract[152]	new[152]	_	_
20-20	2690-2699	radiation	abstract[152]|abstract	new[152]|giv	_	_
20-21	2700-2701	,	abstract[152]	new[152]	_	_
20-22	2702-2713	significant	abstract[152]|quantity[156]	new[152]|new[156]	_	_
20-23	2714-2721	amounts	abstract[152]|quantity[156]	new[152]|new[156]	_	_
20-24	2722-2724	of	abstract[152]|quantity[156]	new[152]|new[156]	_	_
20-25	2725-2728	ROS	abstract[152]|quantity[156]|substance	new[152]|new[156]|giv	coref	22-5
20-26	2729-2732	are	abstract[152]	new[152]	_	_
20-27	2733-2742	generated	abstract[152]	new[152]	_	_
20-28	2743-2744	,	_	_	_	_
20-29	2745-2756	stimulating	_	_	_	_
20-30	2757-2763	nSMase	abstract[158]	new[158]	ana	21-1[0_158]
20-31	2764-2774	production	abstract[158]	new[158]	_	_
20-32	2775-2777	to	_	_	_	_
20-33	2778-2791	significantly	_	_	_	_
20-34	2792-2800	increase	_	_	_	_
20-35	2801-2806	MnSOD	abstract[159]	giv[159]	coref	22-5[164_159]
20-36	2807-2813	levels	abstract[159]	giv[159]	_	_
20-37	2814-2815	.	_	_	_	_

#Text=This may in turn stimulate nSMase .
21-1	2816-2820	This	abstract	giv	_	_
21-2	2821-2824	may	_	_	_	_
21-3	2825-2827	in	_	_	_	_
21-4	2828-2832	turn	_	_	_	_
21-5	2833-2842	stimulate	_	_	_	_
21-6	2843-2849	nSMase	substance	giv	coref	23-9
21-7	2850-2851	.	_	_	_	_

#Text=At this point , ROS levels may be reduced , with the end result of limiting the damage .
22-1	2852-2854	At	_	_	_	_
22-2	2855-2859	this	event[162]	new[162]	_	_
22-3	2860-2865	point	event[162]	new[162]	_	_
22-4	2866-2867	,	_	_	_	_
22-5	2868-2871	ROS	substance|abstract[164]	giv|giv[164]	_	_
22-6	2872-2878	levels	abstract[164]	giv[164]	_	_
22-7	2879-2882	may	_	_	_	_
22-8	2883-2885	be	_	_	_	_
22-9	2886-2893	reduced	_	_	_	_
22-10	2894-2895	,	_	_	_	_
22-11	2896-2900	with	_	_	_	_
22-12	2901-2904	the	abstract[165]	new[165]	_	_
22-13	2905-2908	end	abstract[165]	new[165]	_	_
22-14	2909-2915	result	abstract[165]	new[165]	_	_
22-15	2916-2918	of	_	_	_	_
22-16	2919-2927	limiting	_	_	_	_
22-17	2928-2931	the	abstract[166]	giv[166]	_	_
22-18	2932-2938	damage	abstract[166]	giv[166]	_	_
22-19	2939-2940	.	_	_	_	_

#Text=In the above described series of events , nSMase may play predominant roles .
23-1	2941-2943	In	_	_	_	_
23-2	2944-2947	the	event[167]	new[167]	_	_
23-3	2948-2953	above	event[167]	new[167]	_	_
23-4	2954-2963	described	event[167]	new[167]	_	_
23-5	2964-2970	series	event[167]	new[167]	_	_
23-6	2971-2973	of	event[167]	new[167]	_	_
23-7	2974-2980	events	event[167]|event	new[167]|new	_	_
23-8	2981-2982	,	_	_	_	_
23-9	2983-2989	nSMase	substance	giv	_	_
23-10	2990-2993	may	_	_	_	_
23-11	2994-2998	play	_	_	_	_
23-12	2999-3010	predominant	abstract[170]	new[170]	_	_
23-13	3011-3016	roles	abstract[170]	new[170]	_	_
23-14	3017-3018	.	_	_	_	_
